Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo.




descargar 211.1 Kb.
títuloResumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo.
página6/6
fecha de publicación02.01.2016
tamaño211.1 Kb.
tipoResumen
med.se-todo.com > Documentos > Resumen
1   2   3   4   5   6

70a. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64.

  1. Klugman KP. Editorial commentary: antibiotic selection of multiply resistant pneumococci. Clin Infect Dis 2001; 33: 489-91.

  2. Chen DK, Mcgeer A, De Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–9.

  3. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310–3.

  4. Wise R, Brenwald N, Gill M, Fraise A. Streptococcus pneumoniae resistance to fluoroquinolones. Lancet 1996; 348: 1660.

  5. Goldsmith CE, Moore JE, Murphy PC, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998; 41: 420.

  6. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, Chan RM. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32:701-7.

  7. Weiss K, Restieri C, Gauthier R. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001; 33: 517-22.

  8. Rittenhouse SF, Miller LA, Kaplan RL, Mosely GH, Poupard JA. A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates. Diagn Microbiol Infect Dis 1995; 21: 223-5.

  9. Jones RN, Jacobs MR, Washington JA, Pfaller MA. A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States. Diagn Microbiol Infect Dis 1997; 27: 75-83.

  10. Casellas JM. Epidemiology of bacterial incidence and resistance in community acquired respiratory tract infection in South America. 9th International Congress on Infectious Disease. Buenos Aires 2000; Abstr. 3.002.

  11. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330–5.

  12. Neill AM, Martín JR, Weir R, et al. Community-acquired pneumonia: etiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-6.

  13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50.

  14. Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia: results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157: 36–44.

  15. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157: 47–56.

  16. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000; 283: 749–55.

  17. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998; 12: 741–59.

  18. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350–6.

  19. Rosón B, Carratalá J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, resk classess, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158-65.

  20. Mundy LM, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, Quinn TC. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest 1998; 113: 1201-6.

  21. Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26: 1312–20.

  22. O’Doherty B, Dutchman DA, Pettit R, et al. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40 (Suppl A): 73–81.

  23. Tremolieres F, de Kock F, Pluck N, et al. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 447–53.

  24. Ramirez J, Unowsky J, Talbot GH, et al. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21: 103–17.

  25. Patel T, Desai R, Duff J, et al. Comparison of grepafloxacin (GFX) with clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP) [abstract LM-69]. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997.

  26. Moola S, Hagberg L, Churchyard A, et al. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP) [abstract L-113]. In: Program and abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998.

  27. Sullivan J, Gezon J, Williams-Hopkins D, et al. A double blind, randomized multicenter study in ambulatory community-acquired pneumonia (CAP) comparing trovafloxacin with clarithromycin [abstract LM-73]. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997.

  28. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748–63.

  29. Ortqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110: 1499–506.

  30. Bantar C, Nicola F, Fernandez Canigia L, et al. A pharmacodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. J Chemother 2000; 12: 223-27.

  31. Bantar C, Nicola F, Fernandez Canigia L, et al. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through a pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms. J Chemother 2001; 13: 402-406.

  32. Drusano GL and Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 3: 38-44.

  33. Carbon C, members of the International Study Group. Comparative study of levofloxacin (LVFX) and co-amoxiclav (C0-AC) in the treatment of community-acquired pneumonia (CAP) in adults [abstract LM-70]. In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997.

  34. Saito A, Soejima R. The first comparative study with levofloxacin: a double-blind comparative study of gatifloxacin, a new quinolone, and levofloxacin in pneumonia [abstract L-101]. In: Program and abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998.

  35. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.

  36. Lisby G, Brasholt MS, Teglbjerg MS. Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin. Clin Infect Dis 2001 Aug 1; 33 (3): 415-6.

  37. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin–clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999–2007.

  38. Phillips SL, Branaman-Phillips J. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia. J Am Geriatr Soc 1993; 41: 1071-4.

  39. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34: 1076-83.

  40. Poirier R, Chardon H, Beraud A, Debieuvre D, Petitprez P, Montestruc F, Lilienthal F, Janus C. Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults. Rev Pneumol Clin 1997; 53: 325-31.

  41. Rosón B, Carratalá J, Tubau F, Dorca J, Linares J, Pallares R, Manresa F, Gudiol F. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001;7: 85-96.

  42. Mangi RJ, Peccerillo KM, Ryan J, Berenson C, Greco T, Thornton G, Andriole VT. Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia. Diagn Microbiol Infect Dis 1992; 15: 441-7.

  43. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, Ariza J, Gudiol F. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-8.

  44. Bantar C, Famiglietti A, Goldberg M, The Antimicrobial Committee and The National Surveillance Program (SIR) Participants Group. Three-year surveillance study of nosocomial bacterial resistance in Argentina. Int J Infect Dis 2000; 4: 85-90.

  45. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, Jones RN. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 2001 Aug; 5 (4): 200-14.

  46. Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13: 293-8.

  47. Stein GE, Mantz SL. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia. Hosp Pharm 1995; 30: 132-4.

  48. Fogarty C, Dowell ME, Ellison WT, Vrooman PS, Jr, White BJ, Mayer H. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Resp Dis 1999; 20 (Suppl): S60-S69.

  49. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397-404.

  50. Nathwani D. Place of parenteral cephalosporins in the ambulatory setting: clinical evidence. Drugs 2000; 59 Suppl 3: 37-46.

  51. Bagnulo H, Fortunato C, Villardino S, Esmoris G, Vignolo G. Home management of community-acquired pneumonia:an Uruguayan experience. 9th International Congress on Infectious Diseases. Buenos Aires, Argentina 2000, Abst 70,002.

  52. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000; 31 (Suppl 2): S35-9.

  53. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999 Nov 22; 159 (21): 2576-80.

  54. Tan JS, File TM Jr, Di Persio JR, DiPersio LP, Hamor R, Saravolatz LD, Stout JE. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. Clin Infect Dis 2001 Jun 1; 32 (11): 1562-6.

  55. Hohl P, Buser U, Frei R. Fatal Legionella pneumophila pneumonia: treatment failure despite early sequential oral-parenteral amoxicillin-clavulanic acid therapy. Infection 1992; 20: 99-100.

  56. de Klerk GJ, van Steijn JH, Lobatto S, et al. A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections. Int J Antimicrob Agents 1999; 12: 121-7.

  57. Reingold AL. Role of Legionellae in acute infections of lower respiratory tract. Rev Infect Dis 1988; 10: 1018-28.

  58. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160: 923-929.

  59. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62 (1): 13-59.

  60. Johnson CC, Livornese L, Gold MJ, Pitsakis PG, Taylor S, Levinson ME. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. Antimicrob Agents Chemother 1995; 35: 765-73.

  61. Patterson JE, Hardin TC, Kelly MT, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2000; 21: 455-8.

  62. Zervos M, Nelson M, and the Cefepime Study Group. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42: 729-33.

  63. Speich R, Imhof E, Vogt M, Grossenbacher M, Zimmerli W. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 313-7.

  64. Bantar C, Di Chiara M, Nicola F, Relloso S, Smayevsky J. Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains. Diag Microbiol Infect Dis 2000; 37: 41-4.

  65. Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome and meropenem against 124 strains of Pseudomonas aeruginosa by checkerboard and time-killing methodology. Antimicrob Agents Chemother 1998; 42: 953-5.

  66. Gerceker AA, Gurler B. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 36: 707-11.

  67. Iaconis JP, Pitkin DH, Sheikh W, Nadler HL. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997; 24 (Suppl 2): S191-6.

  68. Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Pharmacotherapy 2001; 21 (7 Pt 2): 89S-94S.

  69. Milkovich G. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. Pharmacotherapy 2001; 21 (7 Pt 2): 83S-88S.

  70. Hirata-Dulas CA, Stein DJ, Guay DR, et al. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 1991; 39: 979-85.

  71. Siegel RE, Halpen NA, Almenoll PN, et al. A prospective randomized study of inpatient i.v. antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 1996; 110: 965-71.

  72. Chan R, Hemeryck L, O`Regan M, et al. Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomized, controlled trial. BJM 1995; 310: 360-2.

  73. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001; 119: 1439-48.

  74. Dowell SF. The best treatment for pneumonia. Arch Inter Med 1999; 159: 2511-12.

  75. Davison R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-750.

  76. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Eng J Med 2001; 344: 665-71.

  77. Mier L, Dreyfuss D, Darchy B, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993; 19: 279-284.

  78. Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999; 115: 178-183.

  79. Levinson ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of lung abscess. Ann Intern Med 1983; 98: 466-71.

  80. Gudiol F, Manressa CT, Pallares R, et al. Clindamycin vs. Penicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch inter Med 1990; 150: 2525-9.

  81. Germaud P, Potrier J, Jacqueme P, et al. Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess. Rev Pneumol Clin 1993; 49: 137-41.





1   2   3   4   5   6

similar:

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconIntentar es conseguir -pide y se te dará-Esther y Jerry Hicks El Mistico
«Pido que todo el mundo, en todo el planeta, lea Intentar es conseguir, porque es un libro sobre sanación, poder y amor escrito de...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconApercepciones sobre el esoterismo islámico y
«La diversidad de los métodos, escribía Guénon el 3 de octubre de 1945, responde a la diversidad misma de las naturalezas individuales...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconEl grupo sanguíneo es la clave para todo el sistema inmune de su...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconNorma oficial Mexicana nom-178-ssa1-1998, Que establece los requisitos...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconResumen la endometriosis es una enfermedad progresiva, que afecta...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconResumen: el objetivo del presente trabajo es estudiar cuales son...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. icon“Se puede viajar por todo el mundo sin ver nada, o se puede ir solamente...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconResumen Las dioxinas constituyen un grupo de compuestos químicos...

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconLas varices son una enfermedad que afecta a las venas de las piernas....

Resumen La neumonía adquirida en la comunidad (nac) es, probablemente, una de las infecciones que afecta a pacientes ambulatorios para la cual se ha escrito la mayor diversidad de guías en todo el mundo. iconResumen en este escrito se señala la importancia de la metrología...


Medicina



Todos los derechos reservados. Copyright © 2015
contactos
med.se-todo.com